OTC Pharmaceuticals in Belgium

OTC Pharmaceuticals in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Belgium otc pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

  • The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), and medicated skin products (anti-bacterials, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2013 annual average exchange rates.
  • The Belgian OTC pharmaceuticals market had total revenues of $976.7m in 2013, representing a compound annual growth rate (CAGR) of 2.1% between 2009 and 2013.
  • The cough and cold preparations segment was the market's most lucrative in 2013, with total revenues of $233.5m, equivalent to 23.9% of the market's overall value.
  • The performance of the market is forecast to follow a similar pattern with an anticipated CAGR of 2.1% for the five-year period 2013 - 2018, which is expected to drive the market to a value of $1,082.5m by the end of 2018.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the otc pharmaceuticals market in Belgium

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Belgium

Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Belgium otc pharmaceuticals market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Belgium economy

Reasons to buy

What was the size of the Belgium otc pharmaceuticals market by value in 2013?

What will be the size of the Belgium otc pharmaceuticals market in 2018?

What factors are affecting the strength of competition in the Belgium otc pharmaceuticals market?

How has the market performed over the last five years?

Companies mentioned

Bayer AG, Johnson & Johnson, Novartis AG and Omega Pharma NV

Bayer AG, Johnson & Johnson, Novartis AG and Omega Pharma NV

Table of Contents

TABLE OF CONTENTS

Executive Summary 2

Market value 2

Market value forecast 2

Category segmentation 2

Geography segmentation 2

Market share 2

Market rivalry 2 ...

TABLE OF CONTENTS

Executive Summary 2

Market value 2

Market value forecast 2

Category segmentation 2

Geography segmentation 2

Market share 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 8

Market value 8

Market Segmentation 9

Category segmentation 9

Geography segmentation 10

Market share 11

Market distribution 12

Market Outlook 13

Market value forecast 13

Five Forces Analysis 14

Summary 14

Buyer power 15

Supplier power 16

New entrants 17

Threat of substitutes 18

Degree of rivalry 19

Leading Companies 20

Bayer AG 20

Johnson & Johnson 24

Novartis AG 27

Omega Pharma NV 31

Macroeconomic Indicators 34

Country Data 34

Appendix 36

Methodology 36

Industry associations 37

Related MarketLine research 37

LIST OF TABLES

Table 1: Belgium OTC pharmaceuticals market value: $ million, 2009–13 8

Table 2: Belgium OTC pharmaceuticals market category segmentation: $ million, 2013 9

Table 3: Belgium OTC pharmaceuticals market geography segmentation: $ million, 2013 10

Table 4: Belgium OTC pharmaceuticals market share: % share, by value, 2013 11

Table 5: Belgium OTC pharmaceuticals market distribution: % share, by value, 2013 12

Table 6: Belgium OTC pharmaceuticals market value forecast: $ million, 2013–18 13

Table 7: Bayer AG: key facts 20

Table 8: Bayer AG: key financials ($) 22

Table 9: Bayer AG: key financials (€) 22

Table 10: Bayer AG: key financial ratios 22

Table 11: Johnson & Johnson: key facts 24

Table 12: Johnson & Johnson: key financials ($) 25

Table 13: Johnson & Johnson: key financial ratios 25

Table 14: Novartis AG: key facts 27

Table 15: Novartis AG: key financials ($) 28

Table 16: Novartis AG: key financial ratios 29

Table 17: Omega Pharma NV: key facts 31

Table 18: Omega Pharma NV: key financials ($) 32

Table 19: Omega Pharma NV: key financials (€) 32

Table 20: Omega Pharma NV: key financial ratios 32

Table 21: Belgium size of population (million), 2009–13 34

Table 22: Belgium gdp (constant 2005 prices, $ billion), 2009–13 34

Table 23: Belgium gdp (current prices, $ billion), 2009–13 34

Table 24: Belgium inflation, 2009–13 35

Table 25: Belgium consumer price index (absolute), 2009–13 35

Table 26: Belgium exchange rate, 2009–13 35

LIST OF FIGURES

Figure 1: Belgium OTC pharmaceuticals market value: $ million, 2009–13 8

Figure 2: Belgium OTC pharmaceuticals market category segmentation: % share, by value, 2013 9

Figure 3: Belgium OTC pharmaceuticals market geography segmentation: % share, by value, 2013 10

Figure 4: Belgium OTC pharmaceuticals market share: % share, by value, 2013 11

Figure 5: Belgium OTC pharmaceuticals market distribution: % share, by value, 2013 12

Figure 6: Belgium OTC pharmaceuticals market value forecast: $ million, 2013–18 13

Figure 7: Forces driving competition in the OTC pharmaceuticals market in Belgium, 2013 14

Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Belgium, 2013 15

Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Belgium, 2013 16

Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Belgium, 2013 17

Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Belgium, 2013 18

Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Belgium, 2013 19

Figure 13: Bayer AG: revenues & profitability 23

Figure 14: Bayer AG: assets & liabilities 23

Figure 15: Johnson & Johnson: revenues & profitability 25

Figure 16: Johnson & Johnson: assets & liabilities 26

Figure 17: Novartis AG: revenues & profitability 29

Figure 18: Novartis AG: assets & liabilities 30

Figure 19: Omega Pharma NV: revenues & profitability 33

Figure 20: Omega Pharma NV: assets & liabilities 33

List of Tables

NA

NA

List of Figures

NA

NA

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports